Clinical trial
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in…
NCT00040651 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Terminated
Key facts
| NCT number | NCT00040651 |
|---|---|
| Title | Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients |
| Official title | Transplantation With T-Cell Depleted Autologous Peripheral Stem Cells for Severe Systemic Sclerosis: A Phase I Dose Escalation Study |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Collaborators | University of Pittsburgh Amgen Industry Genzyme, a Sanofi Company |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Scleroderma, Systemic Sclerosis |
| Intervention type | Drug, Procedure |
| Interventions | Fludarabine, Cyclophosphamide, Thymoglobulin, Leukapheresis, Self bone marrow transplant |
| Enrollment | 15 |
| Start date | Jul 1, 2002 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jul 10, 2002 |
| Last update posted | Dec 28, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: